Bayer is discontinuing its Calantic Digital Solutions AI platform and ceasing Blackford Analysis services, signaling a major retreat from the radiology AI platform sector.
Key Details
- 1Bayer will exit the radiology AI software platform business, discontinuing Calantic and Blackford Analysis offerings.
- 2Calantic was launched in 2022 and built on Blackford's platform, which Bayer fully acquired in 2023.
- 3Blackford's platform currently hosts over 150 third-party AI apps from more than 60 developers across multiple clinical domains.
- 4A dedicated Bayer team will handle the transition, honoring existing contracts; future sale plans for Blackford are not confirmed.
- 5Industry experts suggest the move may trigger a consolidation wave in the radiology AI platform market and signal underlying adoption and integration challenges.
Why It Matters
Bayer’s withdrawal removes a key player and nearly 10% of spending from the global radiology AI platform ecosystem, raising concerns about the long-term viability of the platform model and potentially slowing broader AI adoption in radiology due to market uncertainty and loss of confidence.
Source
AuntMinnie
Related News
•AuntMinnie
Radiology AI Moves From Hype to Operational Accountability
Radiology leaders are shifting focus from curiosity about AI to demanding measurable, accountable operational impact.
•Radiology Business
AI Predicts Breast Cancer Up to Six Years Before Diagnosis
AI technology using mammograms can predict breast cancer risk up to six years in advance.
•AuntMinnie
AI-Based Slab Reconstruction Streamlines Digital Breast Tomosynthesis
AI-driven slab reconstruction in DBT improves workflow efficiency without compromising diagnostic accuracy in breast cancer screening.